Monday, April 21, 2014

Tuesday Features

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. Stephen Zaruby “We... [Read more of this feature]


Gour Medical in talks to expand animal health portfolio

Gour Medical in talks to expand animal health portfolio

Upstart Gour Medical Animal Health, which recently agreed to acquire a portfolio of four products to be reformulated for pet care, is also negotiating for three or four additional products. Serge Goldner “We are leveraging other people’s investments in the human biopharmaceutical industry to in-license products, improve their formulations and enhance... [Read more of this feature]


In conversation with Tony Pullen

In conversation with Tony Pullen

Tony Pullen Tony Pullen is one of the deans of Canadian capital markets. His career in biotech traces its roots to 1985 as an advisor to Cangene, which merged with Emergent BioSolutions (NYSE:EBS) in February. He also was instrumental in raising the initial capital for MDS Health Ventures, which went on to become MDS Capital Corp., formerly a leading... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Veteran banker Michael Mandel has joined Brean Capital

Veteran banker Michael Mandel has joined Brean Capital

Michael Mandel Brean Capital has recently hired veteran healthcare investment banker, Michael Mandel, as managing director of the firm based in New York. Mr. Mandel has over 17 years of experience in healthcare investment banking and has successfully closed over 60 financing and M&A transactions for private, large and small/mid cap public companies... [Read more of this brief]


Cynapsus completes $25-million financing

Cynapsus completes $25-million financing

Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has completed the sale of 38,461,538 units at a price of 65 cents each for gross proceeds of $25-million.  Each unit consists of one common share and one warrant.  Each warrant can be exercised to purchase an additional common share during the next 60 months. The offering was led by M Partners and Noble... [Read more of this brief]


Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting,... [Read more of this brief]


Leerink starts Kindred Biosciences at outperform

Leerink starts Kindred Biosciences at outperform

Leerink Partners has initiated coverage of Kindred Biosciences (NASDAQ:KIN) with an “outperform” rating and a $32 price target based on a forecast of discounted cash flow. The stock closed at $14.66 on Friday. Kindred is focused on bringing therapies for the treatment of dogs, cats, and horses to market. “With three products in pivotal studies... [Read more of this brief]


Roth starts Flamel Technologies at buy

Roth starts Flamel Technologies at buy

Roth Capital Partners has initiated coverage of Flamel Technologies (NASDAQ:FLML) with a “buy’ rating and $20 price target. The stock closed at $13.74 on Thursday. “The impetus for our buy rating is the potential for the company’s Eclat division to drive significant, and near-term, EPS profitability,” writes analyst Scott Henry. “The... [Read more of this brief]


More Posts From Briefs
Google+